Reshaping respiratory care: potential advances in inhaled pharmacotherapy in asthma.

IF 2.5 3区 医学 Q3 PHARMACOLOGY & PHARMACY
Expert Opinion on Pharmacotherapy Pub Date : 2024-08-01 Epub Date: 2024-08-08 DOI:10.1080/14656566.2024.2389258
Boudewijn J H Dierick, Amber A Eikholt, Susanne J van de Hei, Jean W M Muris, Huib A M Kerstjens, Job F M van Boven
{"title":"Reshaping respiratory care: potential advances in inhaled pharmacotherapy in asthma.","authors":"Boudewijn J H Dierick, Amber A Eikholt, Susanne J van de Hei, Jean W M Muris, Huib A M Kerstjens, Job F M van Boven","doi":"10.1080/14656566.2024.2389258","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Asthma is a common disease with a global burden of 358 million patients. Despite improvements in pharmacological and non-pharmacological treatments, many patients still do not achieve complete asthma control. Therefore, innovative pharmacotherapy is important.</p><p><strong>Areas covered: </strong>Following a semi-structured search in Pubmed, an overview of advances in inhaled asthma therapy is provided, looking at innovations in digital inhalers, eco-friendly inhalers and novel inhaled biologic therapies, antibiotics and vaccines, as well as other potential novel asthma therapy targets.</p><p><strong>Expert opinion: </strong>Digital inhalers, sending reminders and monitoring inhalation technique electronically, can support medication adherence and improve asthma control. To reduce the global warming potential of traditional aerosols used in pressurized metered-dose inhalers (HFA-134a, HFA-227ea), greener alternatives are under development (HFA-152a, HFO-1234ze) that are expected to be available by 2025. Current pharmacological advances in asthma therapy are mainly achieved by novel biologicals (anti-IgE, anti-IL5, anti-IL4/13, and anti-TSLP) targeting specific severe asthma phenotypes. While injection is the usual administration route for biologics and vaccines used in asthma, inhalation is an option being explored, although several (mainly formulation) challenges need to be overcome. Other potential novel future inhaled asthma therapies include anti-IL-33/ST2 biologicals and JAK inhibitors, all still requiring more clinical evidence.</p>","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1507-1516"},"PeriodicalIF":2.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14656566.2024.2389258","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Asthma is a common disease with a global burden of 358 million patients. Despite improvements in pharmacological and non-pharmacological treatments, many patients still do not achieve complete asthma control. Therefore, innovative pharmacotherapy is important.

Areas covered: Following a semi-structured search in Pubmed, an overview of advances in inhaled asthma therapy is provided, looking at innovations in digital inhalers, eco-friendly inhalers and novel inhaled biologic therapies, antibiotics and vaccines, as well as other potential novel asthma therapy targets.

Expert opinion: Digital inhalers, sending reminders and monitoring inhalation technique electronically, can support medication adherence and improve asthma control. To reduce the global warming potential of traditional aerosols used in pressurized metered-dose inhalers (HFA-134a, HFA-227ea), greener alternatives are under development (HFA-152a, HFO-1234ze) that are expected to be available by 2025. Current pharmacological advances in asthma therapy are mainly achieved by novel biologicals (anti-IgE, anti-IL5, anti-IL4/13, and anti-TSLP) targeting specific severe asthma phenotypes. While injection is the usual administration route for biologics and vaccines used in asthma, inhalation is an option being explored, although several (mainly formulation) challenges need to be overcome. Other potential novel future inhaled asthma therapies include anti-IL-33/ST2 biologicals and JAK inhibitors, all still requiring more clinical evidence.

重塑呼吸系统护理:哮喘吸入药物疗法的潜在进展。
引言哮喘是一种常见疾病,全球有 3.58 亿患者。尽管药物和非药物治疗有所改进,但许多患者仍无法完全控制哮喘。因此,创新药物疗法非常重要:通过在 Pubmed 上进行半结构化搜索,概述了吸入式哮喘疗法的进展,研究了数字吸入器、环保型吸入器和新型吸入式生物疗法、抗生素和疫苗方面的创新,以及其他潜在的新型哮喘治疗目标:数字吸入器通过电子方式发送提醒信息并监测吸入技术,有助于坚持用药并改善哮喘控制。为了降低加压计量吸入器(HFA-134a、HFA-227ea)中使用的传统气溶胶的全球变暖潜能值,目前正在开发更环保的替代品(HFA-152a、HFO-1234ze),预计将于 2025 年上市。目前,哮喘治疗的药理进步主要是通过针对特定严重哮喘表型的新型生物制剂(抗 IgE、抗 IL5、抗 IL4/13 和抗 TSLP)实现的。虽然注射是治疗哮喘的生物制剂和疫苗的常规给药途径,但吸入也是一种正在探索的选择,不过还需要克服几个(主要是配方)挑战。未来其他潜在的新型吸入式哮喘疗法包括抗IL-33/ST2生物制剂和JAK抑制剂,所有这些疗法都还需要更多的临床证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
3.10%
发文量
163
审稿时长
4-8 weeks
期刊介绍: Expert Opinion on Pharmacotherapy is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds mainly of chemical/synthetic origin, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信